about
The canine copper toxicosis gene MURR1 does not cause non-Wilsonian hepatic copper toxicosisEvidence for genetic heterogeneity in lymphedema-cholestasis syndrome.Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus.IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosisA mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis.Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients.Patient experience in cystic fibrosis care: Development of a disease-specific questionnaire.Cystic fibrosis in Austria.Psychological resilience and intolerance of uncertainty in coping with cystic fibrosis.Long-term improvement of lung clearance index in patients with mild cystic fibrosis lung disease: Does hypertonic saline play a role?International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome.Evaluating patient experience in a cystic fibrosis centre using a disease-specific patient satisfaction questionnaire.Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.Lung clearance index: normal values, repeatability, and reproducibility in healthy children and adolescents.Severe cold agglutinin disease caused by recurrent monomorphic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), clonally related to an EBV-negative plasmacytic hyperplasia in a pediatric multivisceral organ trFeasibility and variability of measuring the Lung Clearance Index in a multi-center setting.Calculation of the capnographic index based on expiratory molar mass-volume-curves--a suitable tool to screen for cystic fibrosis lung disease.Long-term glomerular filtration rate following pediatric liver transplantation.Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis.Faecal calprotectin concentrations in young children with cystic fibrosis.Tracking Lung Clearance Index and chest CT in mild cystic fibrosis lung disease over a period of three years.Low sodium status in cystic fibrosis-as assessed by calculating fractional Na(+) excretion-is associated with decreased growth parameters.Fecal Calprotectin in Cystic Fibrosis and Its Relation to Disease Parameters: A Longitudinal Analysis for 12 Years.Amikacin containing self-emulsifying delivery systems via pulmonary administration for treatment of bacterial infections of cystic fibrosis patients.Cystic fibrosis (CF) care through the patients' eyes - a nationwide survey on experience and satisfaction with services using a disease-specific questionnaire.Spectrum of imaging findings after pediatric liver transplantation: part 1, posttransplantation anatomySpectrum of imaging findings after pediatric liver transplantation: part 2, posttransplantation complicationsSpectrum of imaging findings after intestinal, liver-intestinal, or multivisceral transplantation: part 1, posttransplantation anatomySpectrum of imaging findings after intestinal, liver-intestinal, or multivisceral transplantation: part 2, posttransplantation complicationsHygienic safety of an ultrasonic flow sensor for multiple breath washoutSensitivity of Lung Clearance Index and chest computed tomography in early CF lung diseaseDifferent approaches to evaluate patient experience and satisfaction in CF centresLung clearance index to detect the efficacy of Aztreonam lysine inhalation in patients with cystic fibrosis and near normal spirometry - A single-centre feasibility study
P50
Q28205001-C952315C-0F63-4437-9014-1315FAE8D9BBQ33965643-B7C39837-8C30-4B2C-9DDD-F5A492763CBDQ36197194-69CAC300-6835-4CD6-A978-12BD0DD4EC8EQ36690556-10452CBC-52CF-46E8-8554-D796FC742BDCQ37591319-8748C817-3BDA-41AC-B0EF-ED54173E0E9AQ37887180-7DC01841-A0CA-48D1-8431-B41EFE264EBFQ38224055-57A56833-9AB9-495A-8515-5A93F08FCA64Q38943041-6D6EF1B9-1FAC-4D43-B46B-510CA3C202DFQ39285205-380FB5F3-ED86-415E-83A5-21527BAD7B34Q40719337-890A4370-10D3-491B-A036-5C9858D65DD1Q40880195-FE5FD1AE-32E1-4B06-BAD1-721B1147FAFFQ40972501-F40D58AF-1350-4BB6-BEA3-5A18252310FCQ43880889-6EC52CCE-7944-4D93-A49D-E0A4DCBE289AQ44944879-A9684949-324F-469E-94BD-4F9D75EB3C58Q45401870-72FA6AB4-20E7-439B-9A98-1A8FB09B8342Q45588440-9CB131B6-31B8-447C-8480-DD3315B1B66EQ46421820-262E42B2-0CC3-4E8D-84A3-5FB2B5100400Q46714689-98A03429-D1C0-4C75-A4D9-66A8FC33948FQ47838979-9CC29930-C927-4048-8B66-3761577E04EFQ50137352-AC07088C-3DC6-403B-9E1D-87BD0641BC4BQ50619487-61D50D00-364C-4B01-8F6F-76B0FEEDA95DQ50732864-36286ECA-1BBF-4D9F-B889-3F220B2A3139Q51135321-46AAD283-B57D-4095-A12D-5EA8915F5B72Q52371787-370F9211-FAB5-4C42-AF07-447B7B6516A7Q52871179-BE2A3544-ABDC-4358-8F8E-F40E3BA872B4Q79074084-A7006A8C-FC32-4137-9E53-AB11C737F857Q79074086-2061EB96-C3FC-4BF2-B396-E5357374D688Q80908391-12D9FC5C-50C0-40D7-994D-9B848F842752Q80908395-20CC41E4-FF91-4652-9C67-706C2A67AF15Q82983696-B2364AB0-5904-489D-9356-D8E60CC91963Q84574809-C57A487D-3272-482E-AA88-CD16C1F1C70CQ85370926-82BDAAB3-FF9F-4A19-A65A-F8B0C1AC2E89Q93196295-3B6B760D-EEBF-4FFF-AC2C-EF67A0C02957
P50
description
investigador
@es
researcher
@en
name
Helmut Ellemunter
@en
type
label
Helmut Ellemunter
@en
prefLabel
Helmut Ellemunter
@en
P31
P496
0000-0003-0402-1207